NXY-059 for Acute Ischemic Stroke
The administration of NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did no...
Publications
2 shownInitial Experience of a Digital Training Resource for Modified Rankin Scale Assessment in Clinical Trials
Background and Purpose— The modified Rankin Scale (mRS) is the preferred measure of disability in cerebrovascular clinical trials, but its value is restricted by interobserver v...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 779
- Institution
- AstraZeneca (Sweden)
External Links
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.